Avivagen Announces Peer-Reviewed Journal Publication
05 Fevereiro 2014 - 11:02AM
Access Wire
OTTAWA, ONTARIO, February 5, 2014
- Avivagen Inc. (TSXV:VIV), a wellness
company developing and delivering products that support and enhance
the health and quality of life for animals and the people who care
for them, announces the availability of the first peer-reviewed
scientific journal publication regarding its OxC-beta
technology.
The publication reports novel
discoveries made by Avivagen scientists and collaborators
concerning aspects of the chemistry and biology of ss-carotene that
also relate to the family of 600 carotenoids, including common
health supplements such as ss-carotene, lycopene, lutein and
astaxanthin Although popularly believed to act as an antioxidant,
the new work brings to light the ability of ss-carotene to be
totally transformed by spontaneous reaction with oxygen into
products that collectively demonstrate potential for beneficial
effects upon immune function. The article describes the methods,
compositions and exploratory immunological activity of the class of
natural carotenoid oxidation compounds discovered by Avivagen and
is the first time these findings have been subjected to peer review
and officially published.
Dr. Graham Burton, Director
Commercialization Science and co-founder of Avivagen is the lead
author of the paper and commented "We're very pleased to have our
manuscript reviewed and published by the Canadian Journal of
Chemistry and to make our findings widely available to the
scientific, veterinary and human medical communities. We believe
that our discoveries have important health implications and we look
forward to publishing our further research in this
field."
Cameron Groome, C.E.O. and President of
Avivagen also commented "This publication is important to Avivagen,
as it helps establish the validity of the science underlying our
OxC-beta product line. We look forward to our team and
collaborators publishing future manuscripts concerning the
biological mechanisms of OxC-beta and the benefits from its use in
companion and livestock animals."
The paper, entitled "Beta-Carotene
Autoxidation: Oxygen Copolymerization, Non-Vitamin A Products and
Immunological Activity" was co-authored by Graham W. Burton, Janusz
Daroszewski, James G. Nickerson, James B. Johnson, Trevor J. Mogg
and Grigory B. Nikiforov. A pre-production version of the article
is now available from the Canadian Journal of Chemistry
(published on 3 February 2014,
10.1139/cjc-2013-0494). The Canadian Journal of Chemistry
reports current research findings in all branches of
chemistry, including both traditional and newer interdisciplinary
areas, and the Avivagen paper is freely available on-line at
www.nrcresearchpress.com/journal/cjc.
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life sciences
company trading on the TSX Venture Exchange under the ticker symbol
"VIV". The Company's goal is to develop and deliver
scientifically-proven solutions that can truly benefit companion
and production animals by employing natural mechanisms for
maintaining good health. Avivagen's targeted markets include Pet
Wellness and Livestock Productivity.
The company has sites located in
partnership facilities of the National Research Council of Canada
(NRC) - in Ottawa, Ontario and Charlottetown, Prince Edward
Island. More information can be found
at www.avivagen.com.
About OxC-beta
Avivagen's proprietary and patent-protected technology
is based on its discoveries concerning carotenoid antioxidants. The
novel natural compounds discovered by Avivagen support the body's
own systems to maintain and enhance health, particularly by
supporting immune function. Avivagen's commercial-stage application
of its technology is Fully-Oxidized beta-Carotene (OxC-beta).
OxC-beta compounds occur naturally as carotenoid oxidation products
in vegetation, but in minute amounts. They have been developed to
support the health of companion animals and for use in the global
food animal market.
Research results indicate OxC-beta supports innate
immune function, which can help maintain good health. In pets,
OxC-beta supports overall vitality and energy, mobility and joint
function, skin, coat and gut. Results observed in food animals have
included healthier growth, better utilization of feed and decreased
mortality. In food animals, it is intended that use of OxC-beta
avoids the feeding of antibiotics.
The commercial products of Avivagen are Oximunol(TM)
Chewables, OxC-beta for livestock and Vivamune(TM) Health
Chews.
About Vivamune(TM)
Health Chews - For dogs and cats
Vivamune(TM) Health Chews, containing
Avivagen's proprietary active ingredients, are
scientifically-formulated chews for dogs and cats. Vivamune(TM)
Health Chews work with a pet's own immune system to maintain
overall health and well-being. They are sold in re-sealable
packages of 30 chews and are currently available in the United
States by ordering on-line at www.vivamunehealth.com.
About Oximunol(TM)
Chewables - For dogs
Oximunol(TM) Chewables are scientifically-formulated
chewable tablets that contain Avivagen's proprietary, patented
active ingredient OxC-beta. OxC-beta has been shown to stimulate
innate cellular immunity and may thereby help to maintain overall
health and well-being. Oximunol(TM) Chewables are distributed by
Bayer Healthcare LLC and are available through veterinarians for
dogs of all ages in the United States.
About OxC-beta for Livestock
OxC-beta for Livestock is available as a 10% pre-mix
sold in 1.0 or 5.0 Kg quantities for parts-per-million addition to
animal feeds, in accordance with producer-developed protocols. In
past studies, OxC-beta has been shown to support health and growth
in species such as fish, chicken, pigs and cattle. OxC-beta for
livestock is currently available for commercial sale in the Kingdom
of Thailand.
Forward Looking
Statements
This news release
includes certain forward-looking statements that are based upon
current expectations, which involve risks and uncertainties
associated with the business of Avivagen Inc. and the environment
in which the business operates. Any statements contained herein
that are not statements of historical facts may be deemed to be
forward-looking, including those identified by the expressions
"will", "anticipate", "believe", "plan", "estimate", "expect",
"intend", and similar expressions. The forward-looking statements
reflect the current expectations of Avivagen Inc. regarding future
results or events. These forward-looking statements are subject to
a number of risks and uncertainties that could cause actual results
or events to differ materially from current expectations. Avivagen
assumes no obligation to update the forward-looking statements, or
to update the reasons why actual results could differ from those
reflected in the forward-looking statements.
Neither TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
For more
information:
Avivagen Inc.
Cameron Groome
CEO & President
Phone: 613-949-8164
c.groome@avivagen.com
Avivagen (TSXV:VIV)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Avivagen (TSXV:VIV)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024